Clinical trial
Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients With…
NCT00082472 · Zivena, Industry · Unknown status
Key facts
| NCT number | NCT00082472 |
|---|---|
| Title | Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients With Non-Small-Cell Lung Carcinoma (NSCLC) |
| Official title | Phase I/II Study of Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients With Locally Advanced or Metastatic Unresectable Non Small Cell Lung Cancer |
| Lead sponsor | Zivena, Industry |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | NSCLC |
| Intervention type | Drug |
| Interventions | Doxorubicin HCl Inhalation Solution, Docetaxel, Cisplatin |
| Enrollment | 30 |
| Start date | Jan 1, 2004 |
| First posted | May 12, 2004 |
| Last update posted | Apr 18, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: